Exscientia PLC Precision Design for Precision Oncology Transcript
Hi. I'm Garry Pairaudeau, Exscientia's Chief Technology Officer. Exscientia, our AI platform, is ideally suited for solving multi-parameter drug design problems. This allows us to quickly and efficiently discover novel drug candidates with superior properties. We developed a deep pipeline of programs, including our internal projects, which are focused on precision oncology.
You've heard us talk before about the hallmark of an Exscientia drug being the combination of precision design and personalized medicine. Today, we're going to talk a bit more about the precision design element.
Before we begin, I'd like to remind you that we may make forward-looking statements during this presentation, which are subject to a number of risks and uncertainties, including those described in the slide and the Risk Factors sections of our SEC filings.
Exscientia has led the field of AI-generated molecule design, including putting the first AI-designed compounds into clinical trials. From when the company was founded to where we are today, we have made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
